Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced that its exclusive license with Novartis for the global development and commercialization of emricasan has become effective under terms of the Option, Collaboration and License Agreement signed in December 2016. The license became effective on July 5, 2017, upon Conatus’ receipt of a $7 million payment, which followed U.S. Federal Trade Commission review and expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to the Agreement. Emricasan, Conatus’ first-in-class, orally-active pan-caspase inhibitor, has demonstrated activity across a broad spectrum of liver diseases, and is currently being evaluated in four Phase 2b clinical trials as a potential treatment for liver cirrhosis and fibrosis caused by nonalcoholic steatohepatitis (NASH) or hepatitis C virus (HCV) infection.
On Friday Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) share price closed at $6.51. Company return on equity (ROE) is -107.20%. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) is -30.74% away from its 52 week high.
Vince Holding Corp. (NYSE:VNCE) announced that it has filed a registration statement on Form S-3, including a preliminary prospectus, with the Securities and Exchange Commission for a proposed rights offering to existing stockholders.
Under the proposed Rights Offering, the Company would distribute non-transferrable subscription rights to its existing stockholders as of the record date to be determined, which would entitle the stockholders to purchase additional shares of the Company’s common stock on a pro rata basis. As previously announced, Sun Capital Partners V, L.P., an affiliate of Sun Capital Partners, Inc., has agreed to enter into an investment agreement with the Company to backstop the Rights Offering for up to $30 million. As of the date hereof, affiliates of Sun Capital Partners, Inc. hold approximately 58% of the Company’s outstanding common stock.
Vince Holding Corp. (NYSE:VNCE) traded 2.95 Million shares and its share price increased 24.12% to close at $0.60. Company has 0.30% insider ownership. Vince Holding Corp. (NYSE:VNCE) quarterly performance is -55.67% while its year to date (YTD) performance is -85.22%.
On Friday shares of Pan American Silver Corp. (NASDAQ:PAAS) ended up at $15.47. This year Company’s Earnings per Share (EPS) growth is 143.90% and next year’s EPS growth is 72.29%. Beta of Pan American Silver Corp. (NASDAQ:PAAS) is 0.27 while company weekly performance is -8.68%.
Xilinx, Inc. (NASDAQ:XLNX) increased 1.43% to close at $65.35 on 07 July. Its return on assets (ROA) is 12.80% while return on investment (ROI) is 15.90%. Xilinx, Inc. (NASDAQ:XLNX) price to sales (P/S) ratio is 6.89.